Simulation outcome in relation to the rates of viral spread via contact (bi) and death rate of infected cells (di) in the 3D model for three different forms of viral infection. As indicated in the illustration on the left, virus infection in the tumour is initiated either in the centre (top row), or from the periphery (middle row), or in a random manner (bottom row). For each infection scenario 50,000 simulations were run, which were classified according to (A) their therapeutic outcomes; and (B) the number of the different types of cells at the end of the simulations. All parameters were at their default values. The colour code is based on the logarithm of cell numbers. (TIF)</p
(A) Effect of the probability of becoming resistant (Cr) and the degree of resistance (Rr) on the th...
<p>In all panels A–F, colored curves represent the pathogen population sizes of different virus stra...
Predicted RVFV infection dynamics in mammalian cells for three different scenarios: selective genome...
For three scenarios: (A) absence of virus-resistant cancer cells; (B) production of resistant cancer...
In the graphs of the main text (Fig 3), the rate of virus spread (bi) ranges from 0 to 5, while the ...
(A) Therapeutic outcomes in the 2D Voronoi model in relation to the rates of viral spread via contac...
(A) Effect of the time of treatment (Ti) on the therapeutic outcome in the Voronoi model and 3D mode...
(A) Therapeutic outcome in relation to the rates of viral spread via contact (bi) and death rate of ...
(A) Therapeutic outcomes in the 2D Voronoi model in relation to the rates of viral spread via contac...
In our model, virus infection in the tumour tissue can result in four therapeutic outcomes: (A) tota...
In the Voronoi model, we considered various dispersal distances of the virus. For each dispersal dis...
This figure corresponds to Fig 5 in the main text, which illustrates the effect of start of viral tr...
Effect of the start of virotherapy (Ti) on the therapeutic outcome in the Voronoi, 2D regular and 3D...
Therapeutic outcomes in relation to the birth (bc) and death (dc) rates of cancer cells for the Voro...
Oncolytic virotherapy is a promising form of cancer treatment that uses native or genetically engine...
(A) Effect of the probability of becoming resistant (Cr) and the degree of resistance (Rr) on the th...
<p>In all panels A–F, colored curves represent the pathogen population sizes of different virus stra...
Predicted RVFV infection dynamics in mammalian cells for three different scenarios: selective genome...
For three scenarios: (A) absence of virus-resistant cancer cells; (B) production of resistant cancer...
In the graphs of the main text (Fig 3), the rate of virus spread (bi) ranges from 0 to 5, while the ...
(A) Therapeutic outcomes in the 2D Voronoi model in relation to the rates of viral spread via contac...
(A) Effect of the time of treatment (Ti) on the therapeutic outcome in the Voronoi model and 3D mode...
(A) Therapeutic outcome in relation to the rates of viral spread via contact (bi) and death rate of ...
(A) Therapeutic outcomes in the 2D Voronoi model in relation to the rates of viral spread via contac...
In our model, virus infection in the tumour tissue can result in four therapeutic outcomes: (A) tota...
In the Voronoi model, we considered various dispersal distances of the virus. For each dispersal dis...
This figure corresponds to Fig 5 in the main text, which illustrates the effect of start of viral tr...
Effect of the start of virotherapy (Ti) on the therapeutic outcome in the Voronoi, 2D regular and 3D...
Therapeutic outcomes in relation to the birth (bc) and death (dc) rates of cancer cells for the Voro...
Oncolytic virotherapy is a promising form of cancer treatment that uses native or genetically engine...
(A) Effect of the probability of becoming resistant (Cr) and the degree of resistance (Rr) on the th...
<p>In all panels A–F, colored curves represent the pathogen population sizes of different virus stra...
Predicted RVFV infection dynamics in mammalian cells for three different scenarios: selective genome...